Funding, News and Announcements

This competitive grant offering seeks to enhance the understanding of the need for Homologous Recombination Repair Gene Mutation (HRRm) testing relative to metastatic prostate cancer in clinical practice in accordance with practice guidelines.

Projects that will be considered for Pfizer support will focus on:

• Increasing the understanding of mutations in Homologous Recombination Repair genes in metastatic prostate cancer.
• Discuss and review guidelines relative to testing patients for the presence of HRR mutations in metastatic prostate cancer.
• Support the implementation and appropriate utilization of HRRm testing in clinical practice in accordance with guidelines (including which patients to test and when).

Full call details are available here.

Internal Deadline: October 3, 2023 at 4:30pm. Contact email is ird@dal.ca.

Funder Deadline: October 18, 2023 at 11:59pm. Contact email is Dewayne Brumlow, dewayne.brumlow@pfizer.com